Related references
Note: Only part of the references are listed.Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature
Alessio Mosca et al.
CURRENT NEUROPHARMACOLOGY (2023)
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects
Malin Vedoy Uthaug et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2022)
Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting
Elena Argento et al.
INTERNATIONAL JOURNAL OF DRUG POLICY (2022)
Psychedelics, placebo effects, and set and setting: Insights from common factors theory of psychotherapy
Natalie Gukasyan et al.
TRANSCULTURAL PSYCHIATRY (2022)
Psychedelics alter metaphysical beliefs
Christopher Timmermann et al.
SCIENTIFIC REPORTS (2021)
Psychedelics as Tools for Belief Transmission. Set, Setting, Suggestibility, and Persuasion in the Ritual Use of Hallucinogens
David Dupuis
FRONTIERS IN PSYCHOLOGY (2021)
Who is the typical psychedelics user? Methodological challenges for research in psychedelics use and its consequences
Petter Grahl Johnstad
NORDIC STUDIES ON ALCOHOL AND DRUGS (2021)
Psychedelics and Psychedelic-Assisted Psychotherapy
Collin M. Reiff et al.
AMERICAN JOURNAL OF PSYCHIATRY (2020)
Therapeutic use of serotoninergic hallucinogens: A review of the evidence and of the biological and psychological mechanisms
Rafael Guimaraes dos Santos et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2020)
Population Survey Data Informing the Therapeutic Potential of Classic and Novel Phenethylamine, Tryptamine, and Lysergamide Psychedelics
James Daniel Sexton et al.
FRONTIERS IN PSYCHIATRY (2020)
Psychedelics as an emerging novel intervention in the treatment of substance use disorder: a review
Alec J. DiVito et al.
MOLECULAR BIOLOGY REPORTS (2020)
Examination of Recreational and Spiritual Peyote Use Among American Indian Youth
Mark A. Prince et al.
JOURNAL OF STUDIES ON ALCOHOL AND DRUGS (2019)
Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function
Matthew W. Johnson et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions
Ricardo Jorge Dinis-Oliveira et al.
CURRENT MOLECULAR PHARMACOLOGY (2019)
Global statistics on alcohol, tobacco and illicit drug use: 2017 status report
Amy Peacock et al.
ADDICTION (2018)
Neuroscience of Addiction: Relevance to Prevention and Treatment
Nora D. Volkow et al.
AMERICAN JOURNAL OF PSYCHIATRY (2018)
Psychedelics and the essential importance of context
Robin L. Carhart-Harris et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder
Michael P. Bogenschutz et al.
FRONTIERS IN PHARMACOLOGY (2018)
Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016
James B. Leonard et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2018)
The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Louisa Degenhardt et al.
LANCET PSYCHIATRY (2018)
Trends in DMT and Other Tryptamine Use Among Young Adults in the United States
Joseph J. Palamar et al.
AMERICAN JOURNAL ON ADDICTIONS (2018)
The serotonin 5-HT2C receptor and the non-addictive nature of classic hallucinogens
Clinton E. Canal et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
The association of psychedelic use and opioid use disorders among illicit users in the United States
Vincent D. Pisano et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
An online survey of tobacco smoking cessation associated with naturalistic psychedelic use
Matthew W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2017)
Psychedelic Drugs in Biomedicine
Evan J. Kyzar et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2017)
Exploring the Link Between Substance Use and Mental Health Status: What Can We Learn from the Self-medication Theory?
L. Lerissa Smith et al.
JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED (2017)
Substance Abuse Screening and Treatment
Johnny C. Tenegra et al.
PRIMARY CARE (2016)
Classic hallucinogens in the treatment of addictions
Michael P. Bogenschutz et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2016)
Treatment Access Barriers and Disparities Among Individuals with Co-Occurring Mental Health and Substance Use Disorders: An Integrative Literature Review
Mary Ann Priester et al.
JOURNAL OF SUBSTANCE ABUSE TREATMENT (2016)
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population
Peter S. Hendricks et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Michael P. Bogenschutz et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2015)
LSD enhances suggestibility in healthy volunteers
R. L. Carhart-Harris et al.
PSYCHOPHARMACOLOGY (2015)
An exploration of the dynamic longitudinal relationship between mental health and alcohol consumption: a prospective cohort study
Steven Bell et al.
BMC MEDICINE (2014)
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction
Matthew W. Johnson et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2014)
A survey of hallucinogenic mushroom use, factors related to usage, and perceptions of use among college students
Robert M. Hallock et al.
DRUG AND ALCOHOL DEPENDENCE (2013)
Crosswalk between DSM-IV dependence and DSM-5 substance use disorders for opioids, cannabis, cocaine and alcohol
Wilson M. Compton et al.
DRUG AND ALCOHOL DEPENDENCE (2013)
Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010
Louisa Degenhardt et al.
LANCET (2013)
Psychedelics and Mental Health: A Population Study
Teri S. Krebs et al.
PLOS ONE (2013)
Therapeutic mechanisms of classic hallucinogens in the treatment of addictions: from indirect evidence to testable hypotheses
Michael P. Bogenschutz et al.
DRUG TESTING AND ANALYSIS (2012)
Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Teri S. Krebs et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Serotonergic Hallucinogens and Emerging Targets for Addiction Pharmacotherapies
Stephen Ross
PSYCHIATRIC CLINICS OF NORTH AMERICA (2012)
Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness
Katherine A. MacLean et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2011)
Contributions of serotonin in addiction vulnerability
L. G. Kirby et al.
NEUROPHARMACOLOGY (2011)
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Adam L. Halberstadt et al.
NEUROPHARMACOLOGY (2011)
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Roland R. Griffiths et al.
PSYCHOPHARMACOLOGY (2011)
Adverse Childhood Events and Lifetime Alcohol Dependence
Daniel J. Pilowsky et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2009)
Validation of the nicotine dependence syndrome scale (NDSS): a criterion-group design contrasting chippers and regular smokers
S Shiffman et al.
DRUG AND ALCOHOL DEPENDENCE (2005)
Share Paper
